logo-loader
RNS
4basebio PLC

4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board

4basebio PLC

("4basebio" or the "Company")

–CAMBRIDGE, UKJune 15, 2026–(AIM: 4BB), a specialist in specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, today announces the appointment of , Ph.D., to its Strategic Advisory Board (SAB). A globally recognised figure in mRNA biology and translation, Dr. Coller’s expertise will assist with the Company’s efforts to reshape the scalable manufacturing of next-generation nucleic acid therapeutics.Jeff Coller4basebio PLC

joins 4basebio at a pivotal moment as the Company scales its synthetic DNA technology for mRNA synthesis, AAV vector manufacturing, and state-of-the-art gene editing applications. Dr. Coller’s understanding of translation efficiency and mRNA stability will help guide 4basebio’s strategy to deliver optimised, high-fidelity DNA templates that maximise the therapeutic potential of genetic medicines.Dr. Coller

As 4basebio expands its capabilities, including the highly anticipated transition to its new state-of-the-art manufacturing facility, Dr. Coller’s insights will be instrumental. His presence on the SAB reinforces 4basebio's commitment to bridging high-impact scientific innovation with robust, commercial-scale bioprocessing solutions.Cambridge

Dr. , Chief Executive Officer at 4basebio, commentedAmy Walker:“”Jeff’s groundbreaking discoveries in mRNA stability and translation are nothing short of transformative for our industry. His vision aligns perfectly with 4basebio’s bold mission to dismantle the bottlenecks of traditional manufacturing. With Jeff on our Strategic Advisory Board, we are supercharging our ability to deliver the highest-performing synthetic DNA platforms to our partners - faster, purer, and built for the future of genetic medicine.

added:Dr. Coller“”The future of mRNA therapeutics hinges entirely on the quality and scalability of the starting materials. 4basebio has engineered a truly disruptive approach to synthetic DNA manufacturing that eliminates the legacy challenges of plasmid DNA. I am thrilled to join the Strategic Advisory Board and collaborate with a team that is redefining what is biologically and commercially possible for genetic medicines.

, Ph.D., is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at The Johns Hopkins University and the Inaugural Director of the RNA Innovation Center. With over 30 years dedicated to the study of mRNA, his pioneering research has fundamentally shifted the scientific understanding of gene expression, demonstrating that the genetic code acts as a master determinant of mRNA stability and transcript fate. Dr. Coller’s transformative work has not only shaped foundational RNA biology but has also accelerated the development of life-saving mRNA therapeutics and vaccines. He is the co-founder of Tevard Biosciences, a founding member and Board Director of the Alliance for mRNA Medicines, and an elected Fellow of the American Association for the Advancement of Science (AAAS). He earned his Ph.D. in Cellular and Molecular Biology from the University of Wisconsin-Madison and completed his postdoctoral fellowship at the Howard Hughes Medical Institute.Jeff Coller

 For further enquiries, please contact:

About 4basebio

4basebio (AIM: 4BB) is a -based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.Cambridge

For more information, visit.4basebio.com

Forward-looking statements

This announcement may contain certain statements about the future outlook for 4basebio. Although the directors believe their expectations are based on reasonable assumptions, any statements about future outlook may be influenced by factors that could cause actual outcomes and results to be materially different.

4basebio Appoints Dr. to Strategic Advisory BoardJeff Coller

--          Dr. Coller       ,        a Bloomberg Distinguished
        Professor of RNA Biology and Therapeutics       , brings deep expertise
        to accelerate synthetic DNA and mRNA manufacturing
    --          Dr. Coller’s laboratory team has made seminal discoveries in the
        area of messenger RNA stability and translation
4basebio PLC

    Dr. , CEO

    +44 (0)12 2396 7943

      Cairn Financial Advisers LLP (Nominated Adviser)

     /  / 

    +44 (0)20 7213 0880

      Cavendish Capital Markets Limited (Joint Broker)

     / 

    +44 (0)20 7220 0500

       RBC Capital Markets (Joint Broker)

     / 

    +44 (0)20 7653 4000

      ICR Healthcare (Media and Investor Relations)

      / 

     +44 (0)203 707 5700Amy WalkerJo TurnerSandy JamiesonEd DownesGeoff NashNigel BirksKathryn DeeganMatthew CoakesMary-Jane ElliottJessica Hodgson



NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read